Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Matthew Cooperberg, MD

    TitleAssociate Professor
    SchoolUCSF School of Medicine
    DepartmentUrology
    Address1600 Divisadero St.,MZ Bldg A
    San Francisco CA 94143
    Phone415-353-7171

       Biography 
       Education and Training
      Institution Degree School or Department Year
      Yale UniversityM.D.School of Medicine2000

       Overview 
       Overview
      Health Services

      Both clinician and patient decisions influence the choices about the type of treatment a patient will receive for localized prostate and kidney (renal) cancer. Matthew Cooperberg, MD, MPH is conducting an ongoing research program to study national prostate cancer management trends, based on data from CaPSURE and other sources. His analyses have looked at changes in cancer risk over time, testing and treatment for prostate cancer, local variation in treatment, and the impact of socio-demographic factors on type of treatment and outcomes. Through the creation of a San Francisco General Hospital (SFGH) prostate cancer patient registry, preliminary analysis show that low socioeconomic status patients are treated for a higher percentage of high-risk disease than patients with a higher socioeconomic status. Using data from CaPSURE, the NCDB, SFGH and in collaboration with the Urologic Diseases in America project he continues to explore these topic in depth.


      Prostate Cancer Risk Assessment and Comparative Effectiveness Research

      Properly treating prostate cancer requires determining how likely is it that the cancer will progress. Cooperberg led the team that developed the UCSF-CAPRA score, a prostate cancer risk assessment tool that has been validated in several multi-institutional studies in the U.S. and Europe. CAPRA predicts biochemical recurrence-free survival (PSA level does not rise) after radical prostatectomy with an accuracy at least as good as more mathematically complex nomograms that require complex tables or computer software to calculate and other risk assessment instruments. The score is easy to calculate, and can be used to predict an individual's likelihood of metastasis, cancer-specific mortality, and overall mortality after treatment by surgery, radiation therapy, or androgen deprivation therapy.

      Cooperberg is currently developing a post-operative extension of the CAPRA score (CAPRA-S). After surgery additional information is available from the pathologist's analysis of the removed prostate. This information can help identify men who will benefit from additional therapy such as radiation and/or hormonal therapy after surgery. CAPRA-S will help in that decision making process. Cooperberg is also collaborating with a group of Japanese scientist to develop a prediction instrument specifically applicable to high-risk patients and patients receiving androgen deprivation therapy (J-CAPRA). As new biomarkers, such as genomic and advanced imaging data, are proven valid by UCSF Urology and collaborating laboratory investigators, Cooperberg plans to integrate the information into the current standard measures of risk and outcomes to improve risk assessment. These findings will help men determine with greater confidence whether active surveillance, surgery, radiation, hormonal therapy, or some combination may be most appropriate for them.

      Because accurate risk assessment is essential to compare the effectiveness of different prostate cancer treatments, Cooperberg is currently conducting such comparison studies using CaPSURE data. These data will provide a unique source of insight for future comparative effectiveness research.


      Survivorship

      Cooperberg is collaborating on a project that will lead to better clinical care for cancer survivors. His efforts have helped to develop UCSF’s Urologic Oncology Database (UODB) into a comprehensive data repository for clinical information about patients treated for prostate, bladder, and renal cancers. With the Urology Department’s information experts Cooperberg is developing an automated process to further augment UODB by automatically transferring data from the UCSF Medical Center’s information system into UODB. In collaboration with UCSF Breast Oncology and a health care web services company Cooperberg is developing an electronic survey for cancer patients. Patients will complete a health history and health-related quality of life (HRQOL) survey prior to their first visit to the clinic and at defined intervals after treatment. This effort is expected to help patients and clinicians track HRQOL outcomes, such as urinary and sexual function, after treatment. The survey will help physicians to identify those patients who may need to be seen in clinic more or less frequently.


      Small Renal Masses

      In collaboration with the laboratory of John Kurhanewicz, PhD, Cooperberg is conducting a study to see if magnetic resonance spectroscopy (MRS) can be used to non-invasively diagnosis small renal tumors. MRS is a specialized technique associated with magnetic resonance imaging (MRI). MRS equipment can be used to pick up signals from different chemical nuclei within the body. A preliminary laboratory study is using tissue to identify the specific MRS signals associated with a variety of renal tumors. Once renal tumor signals have been identified, Cooperberg plans to test the ability of MRS to accurately analyze renal tumors in patients. This will be done by using MRS imaging technology on patients who are already scheduled for renal cancer surgery prior to their operation. The pre and post surgery information can be analyzed to determine if the information collected non-invasively by the MRS technology matches the histology and grade of the actual tumor.


       ORNG Applications 
       Websites
       In The News
       More Info

       Bibliographic 
       Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Xia J, Trock BJ, Gulati R, Mallinger L, Cooperberg MR, Carroll PR, Carter HB, Etzioni R. Overdetection of recurrence after radical prostatectomy: estimates based on patient and tumor characteristics. Clin Cancer Res. 2014 Oct 15; 20(20):5302-10.
        View in: PubMed
      2. Vickers AJ, Edwards K, Cooperberg MR, Mushlin AI. A simple schema for informed decision making about prostate cancer screening. Ann Intern Med. 2014 Sep 16; 161(6):441-2.
        View in: PubMed
      3. Rouprêt M, Morgan TM, Bostrom PJ, Cooperberg MR, Kutikov A, Linton KD, Palou J, Martínez-Piñeiro L, van der Poel H, Wijburg C, Winterbottom A, Woo HH, Wirth MP, Catto JW. European association of urology (@uroweb) recommendations on the appropriate use of social media. Eur Urol. 2014 Oct; 66(4):628-32.
        View in: PubMed
      4. Cooperberg MR. Implications of the New AUA Guidelines on Prostate Cancer Detection in the U.S. Curr Urol Rep. 2014 Jul; 15(7):420.
        View in: PubMed
      5. Wang SY, Shiboski S, Belair CD, Cooperberg MR, Simko JP, Stoppler H, Cowan J, Carroll PR, Blelloch R. miR-19, miR-345, miR-519c-5p Serum Levels Predict Adverse Pathology in Prostate Cancer Patients Eligible for Active Surveillance. PLoS One. 2014; 9(6):e98597.
        View in: PubMed
      6. Loeb S, Bayne CE, Frey C, Davies BJ, Averch TD, Woo HH, Stork B, Cooperberg MR, Eggener SE. Use of social media in urology: data from the American Urological Association (AUA). BJU Int. 2014 Jun; 113(6):993-8.
        View in: PubMed
      7. Jalloh M, Cooperberg MR. Implementation of PSA-based active surveillance in prostate cancer. Biomark Med. 2014 Jun; 8(5):747-53.
        View in: PubMed
      8. Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, Febbo PG, Shak S, Kattan MW, Lee M, Carroll PR. A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling. Eur Urol. 2014 May 16.
        View in: PubMed
      9. Porten SP, Smith A, Odisho AY, Litwin MS, Saigal CS, Carroll PR, Cooperberg MR. Updated trends in imaging use in men diagnosed with prostate cancer. Prostate Cancer Prostatic Dis. 2014 May 13.
        View in: PubMed
      10. Welty CJ, Cooperberg MR, Carroll PR. Meaningful end points and outcomes in men on active surveillance for early-stage prostate cancer. Curr Opin Urol. 2014 May; 24(3):288-92.
        View in: PubMed
      11. Cooperberg MR. Prostate cancer: A new look at prostate cancer treatment complications. Nat Rev Clin Oncol. 2014 Jun; 11(6):304-5.
        View in: PubMed
      12. Abern MR, Terris MK, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer. Cancer. 2014 Jun 1; 120(11):1656-62.
        View in: PubMed
      13. Loeb S, Cooperberg MR. Early detection of prostate cancer. Urol Clin North Am. 2014 May; 41(2):xiii.
        View in: PubMed
      14. Morgan TM, Meng MV, Cooperberg MR, Cowan JE, Weinberg V, Carroll PR, Lin DW. A risk-adjusted definition of biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis. 2014 Jun; 17(2):174-9.
        View in: PubMed
      15. Resnick MJ, Barocas DA, Morgans AK, Phillips SE, Chen VW, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Kaplan SH, Paddock LE, Stroup AM, Wu XC, Koyama T, Penson DF. Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: Defining the population at risk for harms of prostate cancer treatment. Cancer. 2014 Apr 15; 120(8):1263-71.
        View in: PubMed
      16. Murphy DG, Ahlering T, Catalona WJ, Crowe H, Crowe J, Clarke N, Cooperberg M, Gillatt D, Gleave M, Loeb S, Roobol M, Sartor O, Pickles T, Wootten A, Walsh PC, Costello AJ. The Melbourne Consensus Statement on the early detection of prostate cancer. BJU Int. 2014 Feb; 113(2):186-8.
        View in: PubMed
      17. van den Bergh RC, Ahmed HU, Bangma CH, Cooperberg MR, Villers A, Parker CC. Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review. Eur Urol. 2014 Jun; 65(6):1023-31.
        View in: PubMed
      18. Moreira DM, Cooperberg MR, Howard LE, Aronson WJ, Kane CJ, Terris MK, Amling CL, Kuchibhatla M, Freedland SJ. Predicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naive men and patients receiving androgen-deprivation therapy: results from the SEARCH database. Prostate Cancer Prostatic Dis. 2014 Mar; 17(1):91-6.
        View in: PubMed
      19. Tseng YD, Paciorek AT, Martin NE, D'Amico AV, Cooperberg MR, Nguyen PL. Impact of national guidelines on brachytherapy monotherapy practice patterns for prostate cancer. Cancer. 2014 Mar 15; 120(6):824-32.
        View in: PubMed
      20. Cary KC, Singla N, Cowan JE, Carroll PR, Cooperberg MR. Impact of Androgen Deprivation Therapy on Mental and Emotional Well-Being in Men with Prostate Cancer: Analysis from the CaPSURE™ Registry. J Urol. 2014 Apr; 191(4):964-70.
        View in: PubMed
      21. Cary KC, Paciorek A, Fuldeore MJ, Carroll PR, Cooperberg MR. Temporal trends and predictors of salvage cancer treatment after failure following radical prostatectomy or radiation therapy: An analysis from the CaPSURE registry. Cancer. 2014 Feb 15; 120(4):507-12.
        View in: PubMed
      22. Li X, Fang D, Cooperberg MR, Whitson JM, Lue TF, Zhou L, Shinohara K. Long-term follow-up of International Prostate Symptom Score (IPSS) in men following prostate brachytherapy. World J Urol. 2014 Aug; 32(4):1061-6.
        View in: PubMed
      23. Moreira DM, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Boffetta P, Freedland SJ. Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: Results from the SEARCH database. Cancer. 2014 Jan 15; 120(2):197-204.
        View in: PubMed
      24. Allott EH, Abern MR, Gerber L, Keto CJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Moorman PG, Freedland SJ. Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. Prostate Cancer Prostatic Dis. 2013 Dec; 16(4):391-7.
        View in: PubMed
      25. Cooperberg MR, Cowan JE, Carroll PR. Reply to A. Azad et al. J Clin Oncol. 2013 Sep 10; 31(26):3296-7.
        View in: PubMed
      26. Cooperberg MR. Re-examining racial disparities in prostate cancer outcomes. J Clin Oncol. 2013 Aug 20; 31(24):2979-80.
        View in: PubMed
      27. Glass AS, Punnen S, Cooperberg MR. Divorcing diagnosis from treatment: contemporary management of low-risk prostate cancer. Korean J Urol. 2013 Jul; 54(7):417-25.
        View in: PubMed
      28. Punnen S, Cowan JE, Dunn LB, Shumay DM, Carroll PR, Cooperberg MR. A longitudinal study of anxiety, depression and distress as predictors of sexual and urinary quality of life in men with prostate cancer. BJU Int. 2013 Jul; 112(2):E67-75.
        View in: PubMed
      29. Punnen S, Cooperberg MR. The epidemiology of high-risk prostate cancer. Curr Opin Urol. 2013 Jul; 23(4):331-6.
        View in: PubMed
      30. Barocas DA, Chen V, Cooperberg M, Goodman M, Graff JJ, Greenfield S, Hamilton A, Hoffman K, Kaplan S, Koyama T, Morgans A, Paddock LE, Phillips S, Resnick MJ, Stroup A, Wu XC, Penson DF. Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study. J Comp Eff Res. 2013 Jul; 2(4):445-60.
        View in: PubMed
      31. Cooperberg MR. Expanding utilization of intensity-modulated radiotherapy for prostate cancer: soaring costs, dubious benefits: comment on "Comparative effectiveness of intensity-modulated radiotherapy and conventional conformal radiotherapy in the treatment of prostate cancer after radical prostatectomy". JAMA Intern Med. 2013 Jun 24; 173(12):1143-4.
        View in: PubMed
      32. Cooperberg MR. Words of wisdom. Re: Quality-of-life effects of prostate-specific antigen screening. Eur Urol. 2013 Jun; 63(6):1130.
        View in: PubMed
      33. Glass AS, Cary KC, Cooperberg MR. Risk-based prostate cancer screening: who and how? Curr Urol Rep. 2013 Jun; 14(3):192-8.
        View in: PubMed
      34. Akaza H, Hinotsu S, Cooperberg MR, Chung BH, Youl Lee J, Umbas R, Tsukamoto T, Namiki M, Carroll P. Sixth joint meeting of J-CaP and CaPSURE--a multinational perspective on prostate cancer management and patient outcomes. Jpn J Clin Oncol. 2013 Jul; 43(7):756-66.
        View in: PubMed
      35. Glass AS, Cowan JE, Fuldeore MJ, Cooperberg MR, Carroll PR, Kenfield SA, Greene KL. Patient demographics, quality of life, and disease features of men with newly diagnosed prostate cancer: trends in the PSA era. Urology. 2013 Jul; 82(1):60-5.
        View in: PubMed
      36. Punnen S, Cooperberg MR, D'Amico AV, Karakiewicz PI, Moul JW, Scher HI, Schlomm T, Freedland SJ. Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2013 Dec; 64(6):905-15.
        View in: PubMed
      37. Punnen S, Freedland SJ, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Carroll PR, Cooperberg MR. Multi-institutional Validation of the CAPRA-S Score to Predict Disease Recurrence and Mortality After Radical Prostatectomy. Eur Urol. 2014 Jun; 65(6):1171-7.
        View in: PubMed
      38. Etzioni R, Gulati R, Cooperberg MR, Penson DM, Weiss NS, Thompson IM. Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening. Med Care. 2013 Apr; 51(4):295-300.
        View in: PubMed
      39. Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S, Gutin A, Lanchbury JS, Swanson GP, Stone S, Carroll PR. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol. 2013 Apr 10; 31(11):1428-34.
        View in: PubMed
      40. Punnen S, Meng MV, Cooperberg MR, Greene KL, Cowan JE, Carroll PR. How does robot-assisted radical prostatectomy (RARP) compare with open surgery in men with high-risk prostate cancer? BJU Int. 2013 Aug; 112(4):E314-20.
        View in: PubMed
      41. Blaschko SD, Weiss DA, Odisho AY, Greene KL, Cooperberg MR. Proximal bulbar periurethral abscess. Int Braz J Urol. 2013 Jan-Feb; 39(1):137-8.
        View in: PubMed
      42. Cooperberg MR, Ramakrishna NR, Duff SB, Hughes KE, Sadownik S, Smith JA, Tewari AK. Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis. BJU Int. 2013 Mar; 111(3):437-50.
        View in: PubMed
      43. Glass AS, Cooperberg MR, Meng MV, Carroll PR. Role of active surveillance in the management of localized prostate cancer. J Natl Cancer Inst Monogr. 2012 Dec; 2012(45):202-6.
        View in: PubMed
      44. Cooperberg MR. Factors associated with treatment received by men diagnosed with prostate cancer in queensland, australia. BJU Int. 2012 Dec; 110(11 Pt B):E720.
        View in: PubMed
      45. Xia J, Trock BJ, Cooperberg MR, Gulati R, Zeliadt SB, Gore JL, Lin DW, Carroll PR, Carter HB, Etzioni R. Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res. 2012 Oct 1; 18(19):5471-8.
        View in: PubMed
      46. Porten SP, Cooperberg MR. High-risk nonmuscle invasive bladder cancer: definition and epidemiology. Curr Opin Urol. 2012 Sep; 22(5):385-9.
        View in: PubMed
      47. Odisho AY, Berry AB, Ahmad AE, Cooperberg MR, Carroll PR, Konety BR. Reply to Jai Prakash, Apul Goel and Manish Garg's Letter to the Editor re: Anobel Y. Odisho, Anna B. Berry, Ardalan E. Ahmad, Matthew R. Cooperberg, Peter R. Carroll, Badrinath R. Konety. Reflex ImmunoCyt Testing for the Diagnosis of Bladder Cancer in Patients with Atypical Urine Cytology. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.04.019. Eur Urol. 2012 Nov; 62(5):e88.
        View in: PubMed
      48. Glass AS, Cooperberg MR, Carroll PR. Early detection of prostate cancer: more information, more clarity. Eur Urol. 2012 Nov; 62(5):753-5; discussion 755-6.
        View in: PubMed
      49. Cooperberg MR, Chan JM. Editorial comment. Urology. 2012 Aug; 80(2):305-6.
        View in: PubMed
      50. Cooperberg MR. Will biomarkers save prostate cancer screening? Eur Urol. 2012 Dec; 62(6):962-3; discussion 964-5.
        View in: PubMed
      51. Kutikov A, Cooperberg MR, Paciorek AT, Uzzo RG, Carroll PR, Boorjian SA. Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram. Prostate Cancer Prostatic Dis. 2012 Dec; 15(4):374-9.
        View in: PubMed
      52. Dall'Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C, Soloway MS. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol. 2012 Dec; 62(6):976-83.
        View in: PubMed
      53. Reese AC, Cowan JE, Brajtbord JS, Harris CR, Carroll PR, Cooperberg MR. The quantitative Gleason score improves prostate cancer risk assessment. Cancer. 2012 Dec 15; 118(24):6046-54.
        View in: PubMed
      54. Cooperberg MR. Urological cancer: For localized prostate cancer, does technology equal progress? Nat Rev Clin Oncol. 2012 Jul; 9(7):371-2.
        View in: PubMed
      55. Cooperberg MR. To predict the future, consider the present as well as the past. Eur Urol. 2012 Jul; 62(1):53-4.
        View in: PubMed
      56. Odisho AY, Berry AB, Ahmad AE, Cooperberg MR, Carroll PR, Konety BR. Reflex ImmunoCyt testing for the diagnosis of bladder cancer in patients with atypical urine cytology. Eur Urol. 2013 May; 63(5):936-40.
        View in: PubMed
      57. Cooperberg MR. Thwarting high-risk prostate cancer: the right treatments for the right patients. Eur Urol. 2012 Jun; 61(6):1107-9.
        View in: PubMed
      58. Aaronson DS, Odisho AY, Hills N, Cress R, Carroll PR, Dudley RA, Cooperberg MR. Proton beam therapy and treatment for localized prostate cancer: if you build it, they will come. Arch Intern Med. 2012 Feb 13; 172(3):280-3.
        View in: PubMed
      59. Akaza H, Carroll P, Cooperberg MR, Hinotsu S. Fifth Joint Meeting of J-CaP and CaPSURE: advancing the global understanding of prostate cancer and its management. Jpn J Clin Oncol. 2012 Mar; 42(3):226-36.
        View in: PubMed
      60. Cooperberg MR, Odisho AY, Carroll PR. Outcomes for radical prostatectomy: is it the singer, the song, or both? J Clin Oncol. 2012 Feb 10; 30(5):476-8.
        View in: PubMed
      61. Cooperberg MR. Adverse effects of androgen deprivation and the limits of national tumor registries. Eur Urol. 2012 Apr; 61(4):701-3; discussion 703-4.
        View in: PubMed
      62. Tasian GE, Cooperberg MR, Potter MB, Cowan JE, Greene KL, Carroll PR, Chan JM. PSA screening: determinants of primary-care physician practice patterns. Prostate Cancer Prostatic Dis. 2012 Jun; 15(2):189-94.
        View in: PubMed
      63. Cooperberg MR. High-risk prostate cancer: treat the prostate. Lancet. 2011 Dec 17; 378(9809):2056-7.
        View in: PubMed
      64. Wu AK, Reese AC, Cooperberg MR, Sadetsky N, Shinohara K. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):100-5.
        View in: PubMed
      65. Cooperberg MR. External-beam radiation therapy should be given with androgen deprivation treatment for intermediate-risk prostate cancer: new confirmatory evidence. Asian J Androl. 2012 Jan; 14(1):132-3.
        View in: PubMed
      66. Punnen S, Cooperberg MR, Sadetsky N, Carroll PR. Among potent men post radical prostatectomy, does the need for phosphodiesterase inhibitors have an impact on sexual bother scores? BJU Int. 2012 May; 109(10):1520-4.
        View in: PubMed
      67. Cooperberg MR. Words of wisdom. Re: Radical prostatectomy versus watchful waiting in early prostate cancer. Eur Urol. 2011 Oct; 60(4):868-9.
        View in: PubMed
      68. Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, Hembroff L, Sadetsky N, Saigal CS, Litwin MS, Klein E, Kibel AS, Hamstra DA, Pisters LL, Kuban DA, Kaplan ID, Wood DP, Ciezki J, Dunn RL, Carroll PR, Sanda MG. Prediction of erectile function following treatment for prostate cancer. JAMA. 2011 Sep 21; 306(11):1205-14.
        View in: PubMed
      69. Punnen S, Cooperberg MR, Sadetsky N, Carroll PR. Androgen deprivation therapy and cardiovascular risk. J Clin Oncol. 2011 Sep 10; 29(26):3510-6.
        View in: PubMed
      70. Cooperberg MR, Carroll PR, Klotz L. Active surveillance for prostate cancer: progress and promise. J Clin Oncol. 2011 Sep 20; 29(27):3669-76.
        View in: PubMed
      71. Cooperberg MR, Mallin K, Kane CJ, Carroll PR. Treatment trends for stage I renal cell carcinoma. J Urol. 2011 Aug; 186(2):394-9.
        View in: PubMed
      72. Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer. 2011 Nov 15; 117(22):5039-46.
        View in: PubMed
      73. Cooperberg MR. Editorial comment. Urology. 2011 Jun; 77(6):1336-7.
        View in: PubMed
      74. Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, Perez N, Greene KL, Meng MV, Carroll PR. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol. 2011 Jul 10; 29(20):2795-800.
        View in: PubMed
      75. Whitson JM, Porten SP, Cowan JE, Simko JP, Cooperberg MR, Carroll PR. Factors associated with downgrading in patients with high grade prostate cancer. Urol Oncol. 2013 May; 31(4):442-7.
        View in: PubMed
      76. Whitson JM, Porten SP, Hilton JF, Cowan JE, Perez N, Cooperberg MR, Greene KL, Meng MV, Simko JP, Shinohara K, Carroll PR. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol. 2011 May; 185(5):1656-60.
        View in: PubMed
      77. Sadetsky N, Greene K, Cooperberg MR, Hubbard A, Carroll PR, Satariano W. Impact of androgen deprivation on physical well-being in patients with prostate cancer: analysis from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry. Cancer. 2011 Oct 1; 117(19):4406-13.
        View in: PubMed
      78. Porten SP, Cooperberg MR, Konety BR, Carroll PR. The example of CaPSURE: lessons learned from a national disease registry. World J Urol. 2011 Jun; 29(3):265-71.
        View in: PubMed
      79. Carroll PR, Whitson JM, Cooperberg MR. Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes? J Clin Oncol. 2011 Feb 1; 29(4):345-7.
        View in: PubMed
      80. Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol. 2011 Jan 10; 29(2):235-41.
        View in: PubMed
      81. Cooperberg MR, Cowan JE, Hilton JF, Reese AC, Zaid HB, Porten SP, Shinohara K, Meng MV, Greene KL, Carroll PR. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol. 2011 Jan 10; 29(2):228-34.
        View in: PubMed
      82. Reese AC, Sadetsky N, Carroll PR, Cooperberg MR. Inaccuracies in assignment of clinical stage for localized prostate cancer. Cancer. 2011 Jan 15; 117(2):283-9.
        View in: PubMed
      83. Cooperberg MR, Vickers AJ, Broering JM, Carroll PR. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer. 2010 Nov 15; 116(22):5226-34.
        View in: PubMed
      84. Porten SP, Richardson DA, Odisho AY, McAninch JW, Carroll PR, Cooperberg MR. Disproportionate presentation of high risk prostate cancer in a safety net health system. J Urol. 2010 Nov; 184(5):1931-6.
        View in: PubMed
      85. Tasian GE, Cooperberg MR, Cowan JE, Keyashian K, Greene KL, Daniels NA, Carroll PR, Chan JM. Prostate specific antigen screening for prostate cancer: knowledge of, attitudes towards, and utilization among primary care physicians. Urol Oncol. 2012 Mar-Apr; 30(2):155-60.
        View in: PubMed
      86. Eisner BH, Zargooshi J, Berger AD, Cooperberg MR, Doyle SM, Sheth S, Stoller ML. Gender differences in subcutaneous and perirenal fat distribution. Surg Radiol Anat. 2010 Nov; 32(9):879-82.
        View in: PubMed
      87. Castle SM, Cooperberg MR, Sadetsky N, Eisner BH, Stoller ML. Adequacy of a single 24-hour urine collection for metabolic evaluation of recurrent nephrolithiasis. J Urol. 2010 Aug; 184(2):579-83.
        View in: PubMed
      88. Vickers AJ, Salz T, Basch E, Cooperberg MR, Carroll PR, Tighe F, Eastham J, Rosen RC. Electronic patient self-assessment and management (SAM): a novel framework for cancer survivorship. BMC Med Inform Decis Mak. 2010; 10:34.
        View in: PubMed
      89. Cooperberg MR. Specialist visits (urologist, radiation oncologist, medical oncologist) are strongly associated with treatment received for prostate cancer in the USA. Evid Based Med. 2010 Jun; 15(3):95-6.
        View in: PubMed
      90. Reese AC, Cooperberg MR, Carroll PR. Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease. J Urol. 2010 Jul; 184(1):114-9.
        View in: PubMed
      91. Odisho AY, Cooperberg MR, Fradet V, Ahmad AE, Carroll PR. Urologist density and county-level urologic cancer mortality. J Clin Oncol. 2010 May 20; 28(15):2499-504.
        View in: PubMed
      92. Le JD, Cooperberg MR, Sadetsky N, Hittelman AB, Meng MV, Cowan JE, Latini DM, Carroll PR. Changes in specific domains of sexual function and sexual bother after radical prostatectomy. BJU Int. 2010 Oct; 106(7):1022-9.
        View in: PubMed
      93. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010 Mar 1; 28(7):1117-23.
        View in: PubMed
      94. Seo Y, Aparici CM, Cooperberg MR, Konety BR, Hawkins RA. In vivo tumor grading of prostate cancer using quantitative 111In-capromab pendetide SPECT/CT. J Nucl Med. 2010 Jan; 51(1):31-6.
        View in: PubMed
      95. Porten SP, Cooperberg MR, Carroll PR. The independent value of tumour volume in a contemporary cohort of men treated with radical prostatectomy for clinically localized disease. BJU Int. 2010 Feb; 105(4):472-5.
        View in: PubMed
      96. Cooperberg MR, Hinotsu S, Namiki M, Ito K, Broering J, Carroll PR, Akaza H. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol. 2009 Sep 10; 27(26):4306-13.
        View in: PubMed
      97. Cooperberg MR, Hinotsu S, Chancellor MB, Homma Y, Nelson PS, Matsuyama H, Menon M, Kucuk O, Hara I, Egawa S, Uzzo RG, Kanayama HO, Okuyama A, Akaza H. Fourth joint meeting of the American Urological Association and the Japanese Urological Association Specialty Society program at the 104th annual meeting of the American Urological Association at Chicago 2009. Int J Urol. 2009 Aug; 16(8):703-8.
        View in: PubMed
      98. Cooperberg MR, Carroll PR. Prostate-cancer screening. N Engl J Med. 2009 Jul 9; 361(2):203; author reply 204-5.
        View in: PubMed
      99. Cooperberg MR, Birkmeyer JD, Litwin MS. Defining high quality health care. Urol Oncol. 2009 Jul-Aug; 27(4):411-6.
        View in: PubMed
      100. Cooperberg MR, Porter MP, Konety BR. Candidate quality of care indicators for localized bladder cancer. Urol Oncol. 2009 Jul-Aug; 27(4):435-42.
        View in: PubMed
      101. Cooperberg MR, Kane CJ, Cowan JE, Carroll PR. Adequacy of lymphadenectomy among men undergoing robot-assisted laparoscopic radical prostatectomy. BJU Int. 2010 Jan; 105(1):88-92.
        View in: PubMed
      102. Cooperberg MR, Broering JM, Carroll PR. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst. 2009 Jun 16; 101(12):878-87.
        View in: PubMed
      103. Cooperberg MR, Konety BR. Management of localized prostate cancer in men over 65 years. Curr Opin Urol. 2009 May; 19(3):309-14.
        View in: PubMed
      104. Eisenberg ML, Davies BJ, Cooperberg MR, Cowan JE, Carroll PR. Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol. 2010 Apr; 57(4):622-9.
        View in: PubMed
      105. Berger AD, Wu W, Eisner BH, Cooperberg MR, Duh QY, Stoller ML. Patients with primary hyperparathyroidism--why do some form stones? J Urol. 2009 May; 181(5):2141-5.
        View in: PubMed
      106. Konety BR, Cooperberg MR, Carroll PR. Are age-based criteria the best way to determine eligibility for prostate cancer screening? Ann Intern Med. 2009 Feb 3; 150(3):220-1; author reply 221-2.
        View in: PubMed
      107. Odisho AY, Fradet V, Cooperberg MR, Ahmad AE, Carroll PR. Geographic distribution of urologists throughout the United States using a county level approach. J Urol. 2009 Feb; 181(2):760-5; discussion 765-6.
        View in: PubMed
      108. Cooperberg MR. Prostate cancer risk assessment: choosing the sharpest tool in the shed. Cancer. 2008 Dec 1; 113(11):3062-6.
        View in: PubMed
      109. Wu AK, Cooperberg MR, Sadetsky N, Carroll PR. Health related quality of life in patients treated with multimodal therapy for prostate cancer. J Urol. 2008 Dec; 180(6):2415-22; discussion 2422.
        View in: PubMed
      110. Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer. 2008 Jul 1; 113(1):78-83.
        View in: PubMed
      111. Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, Meng MV, Kane CJ, Perez N, Master VA, Carroll PR. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer. 2008 Jun 15; 112(12):2664-70.
        View in: PubMed
      112. Cooperberg MR, Mallin K, Ritchey J, Villalta JD, Carroll PR, Kane CJ. Decreasing size at diagnosis of stage 1 renal cell carcinoma: analysis from the National Cancer Data Base, 1993 to 2004. J Urol. 2008 Jun; 179(6):2131-5.
        View in: PubMed
      113. Dall'Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L, Bailey DE, Wallace ME, Kantoff PW, Carroll PR. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer. 2008 Apr 15; 112(8):1650-9.
        View in: PubMed
      114. Cooperberg MR, Cowan J, Broering JM, Carroll PR. High-risk prostate cancer in the United States, 1990-2007. World J Urol. 2008 Jun; 26(3):211-8.
        View in: PubMed
      115. Cooperberg MR, Duh QY, Stackhouse GB, Stoller ML. Oral calcium supplementation associated with decreased likelihood of nephrolithiasis prior to surgery for hyperparathyroidism. Int J Urol. 2007 Dec; 14(12):1113-5.
        View in: PubMed
      116. Whitson JM, Cooperberg MR, Stackhouse GB, Stoller ML. Urinary citrate levels do not correlate with urinary pH in patients with urinary stone formation. Urology. 2007 Oct; 70(4):634-7.
        View in: PubMed
      117. Cooperberg MR, McAninch JW, Alsikafi NF, Elliott SP. Urethral reconstruction for traumatic posterior urethral disruption: outcomes of a 25-year experience. J Urol. 2007 Nov; 178(5):2006-10; discussion 2010.
        View in: PubMed
      118. Cooperberg MR, Modak S, Konety BR. Trends in regionalization of inpatient care for urological malignancies, 1988 to 2002. J Urol. 2007 Nov; 178(5):2103-8; discussion 2108.
        View in: PubMed
      119. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007 Sep; 178(3 Pt 2):S14-9.
        View in: PubMed
      120. Cooperberg MR, Freedland SJ, Pasta DJ, Elkin EP, Presti JC, Amling CL, Terris MK, Aronson WJ, Kane CJ, Carroll PR. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer. 2006 Nov 15; 107(10):2384-91.
        View in: PubMed
      121. Latini DM, Elkin EP, Cooperberg MR, Sadetsky N, Duchane J, Carroll PR. Differences in clinical characteristics and disease-free survival for Latino, African American, and non-Latino white men with localized prostate cancer: data from CaPSURE. Cancer. 2006 Feb 15; 106(4):789-95.
        View in: PubMed
      122. Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol. 2005 Nov 10; 23(32):8146-51.
        View in: PubMed
      123. Greene KL, Cowan JE, Cooperberg MR, Meng MV, DuChane J, Carroll PR. Who is the average patient presenting with prostate cancer? Urology. 2005 Nov; 66(5 Suppl):76-82.
        View in: PubMed
      124. Bassett WW, Cooperberg MR, Sadetsky N, Silva S, DuChane J, Pasta DJ, Chan JM, Anast JW, Carroll PR, Kane CJ. Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology. 2005 Nov; 66(5):1060-5.
        View in: PubMed
      125. Cooperberg MR, Chi T, Jad A, Cha I, Turek PJ. Variability in testis biopsy interpretation: implications for male infertility care in the era of intracytoplasmic sperm injection. Fertil Steril. 2005 Sep; 84(3):672-7.
        View in: PubMed
      126. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, Carroll PR. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005 Jun; 173(6):1938-42.
        View in: PubMed
      127. Camargo AH, Cooperberg MR, Ershoff BD, Rubenstein JN, Meng MV, Stoller ML. Laparoscopic management of peripelvic renal cysts: University of California, San Francisco, experience and review of literature. Urology. 2005 May; 65(5):882-7.
        View in: PubMed
      128. Mitchell JA, Cooperberg MR, Elkin EP, Lubeck DP, Mehta SS, Kane CJ, Carroll PR. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J Urol. 2005 Apr; 173(4):1126-31.
        View in: PubMed
      129. Anast JW, Sadetsky N, Pasta DJ, Bassett WW, Latini D, DuChane J, Chan JM, Cooperberg MR, Carroll PR, Kane CJ. The impact of obesity on health related quality of life before and after radical prostatectomy (data from CaPSURE). J Urol. 2005 Apr; 173(4):1132-8.
        View in: PubMed
      130. Kane CJ, Bassett WW, Sadetsky N, Silva S, Wallace K, Pasta DJ, Cooperberg MR, Chan JM, Carroll PR. Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE. J Urol. 2005 Mar; 173(3):732-6.
        View in: PubMed
      131. Cooperberg MR, Stoller ML. Percutaneous neuromodulation. Urol Clin North Am. 2005 Feb; 32(1):71-8, vii.
        View in: PubMed
      132. Cooperberg MR, Park S, Carroll PR. Prostate cancer 2004: insights from national disease registries. Oncology (Williston Park). 2004 Sep; 18(10):1239-47; discussion 1248-50, 1256-8.
        View in: PubMed
      133. Greene KL, Meng MV, Elkin EP, Cooperberg MR, Pasta DJ, Kattan MW, Wallace K, Carroll PR. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from cancer of the prostate strategic urological research endeavor (capsure). J Urol. 2004 Jun; 171(6 Pt 1):2255-9.
        View in: PubMed
      134. Cooperberg MR, Broering JM, Latini DM, Litwin MS, Wallace KL, Carroll PR. Patterns of practice in the United States: insights from CaPSURE on prostate cancer management. Curr Urol Rep. 2004 Jun; 5(3):166-72.
        View in: PubMed
      135. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004 Jun 1; 22(11):2141-9.
        View in: PubMed
      136. Cooperberg MR, Downs TM, Carroll PR. Radical retropubic prostatectomy frustrated by prior laparoscopic mesh herniorrhaphy. Surgery. 2004 Apr; 135(4):452-3; discussion 454.
        View in: PubMed
      137. Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, Carroll PR. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol. 2004 Apr; 171(4):1393-401.
        View in: PubMed
      138. Liu B, Conrad F, Cooperberg MR, Kirpotin DB, Marks JD. Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells. Cancer Res. 2004 Jan 15; 64(2):704-10.
        View in: PubMed
      139. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol. 2003 Dec; 170(6 Pt 2):S21-5; discussion S26-7.
        View in: PubMed
      140. Cooperberg MR, Small EJ, D'Amico A, Carroll PR. The evolving role of androgen deprivation therapy in the management of prostate cancer. Minerva Urol Nefrol. 2003 Dec; 55(4):219-38.
        View in: PubMed
      141. Harlan SR, Cooperberg MR, Elkin E, Lubeck DP, Meng M, Mehta SS, Carroll PR. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol. 2003 Nov; 170(5):1804-7.
        View in: PubMed
      142. Cooperberg M, Lubeck DP, Penson D, Mehta SS, Carroll PR, Kane CJ. Sociodemographic and clinical risk characteristics of patients with prostate cancer within the Veterans Affairs health care system: data from CaPSURE. J Urol. 2003 Sep; 170(3):905-8.
        View in: PubMed
      143. Cooperberg MR, Master VA, Carroll PR. Health related quality of life significance of single pad urinary incontinence following radical prostatectomy. J Urol. 2003 Aug; 170(2 Pt 1):512-5.
        View in: PubMed
      144. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst. 2003 Jul 2; 95(13):981-9.
        View in: PubMed
      145. Cooperberg MR, Koppie TM, Lubeck DP, Ye J, Grossfeld GD, Mehta SS, Carroll PR. How potent is potent? Evaluation of sexual function and bother in men who report potency after treatment for prostate cancer: data from CaPSURE. Urology. 2003 Jan; 61(1):190-6.
        View in: PubMed
      146. Cooperberg MR, Lubeck DP, Grossfeld GD, Mehta SS, Carroll PR. Contemporary trends in imaging test utilization for prostate cancer staging: data from the cancer of the prostate strategic urologic research endeavor. J Urol. 2002 Aug; 168(2):491-5.
        View in: PubMed
      147. Goldstein LJ, Davies RR, Rizzo JA, Davila JJ, Cooperberg MR, Shaw RK, Kopf GS, Elefteriades JA. Stroke in surgery of the thoracic aorta: incidence, impact, etiology, and prevention. J Thorac Cardiovasc Surg. 2001 Nov; 122(5):935-45.
        View in: PubMed
      148. Cooperberg MR, Fiedler PN. Ki-1 anaplastic large-cell lymphoma occurring at the site of ileocolonic anastomosis in a patient treated surgically for colonic adenocarcinoma: case report and review of the literature. Ann Diagn Pathol. 2001 Jun; 5(3):162-7.
        View in: PubMed
      149. Cooperberg MR, Chambers SK, Rutherford TJ, Foster HE. Cystic pelvic pathology presenting as falsely elevated post-void residual urine measured by portable ultrasound bladder scanning: report of 3 cases and review of the literature. Urology. 2000 Apr; 55(4):590.
        View in: PubMed
      150. Shrimdkandada S, Fu SQ, Yin LH, Guo XY, Nanakorn T, Peng XY, Dizon D, Lin D, Cooperberg M, Won JH, Deisseroth A. Methods for Chemoprotection and Chemosensitization : MDR-1 For Chemoprotection Using Retroviruses to Modify Hematopoietic Cells and Cytosine Deaminase for Chemosensitization Using Adenoviral Vectors to Modify Epithelian Neoplastic Cells. Methods Mol Med. 2000; 35:609-16.
        View in: PubMed
      151. Garcia-Sanchez F, Pizzorno G, Fu SQ, Nanakorn T, Krause DS, Liang J, Adams E, Leffert JJ, Yin LH, Cooperberg MR, Hanania E, Wang WL, Won JH, Peng XY, Cote R, Brown R, Burtness B, Giles R, Crystal R, Deisseroth AB. Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologous transplantation. Blood. 1998 Jul 15; 92(2):672-82.
        View in: PubMed
      Matthew's Networks
      Related Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Related Authors
      People who share related concepts with this person.
      _
      Back to TOP